Aarti Pharmalabs Operations Uninterrupted Despite Regulatory Scrutiny; Delhi High Court Imposes Restrictions on Ruxolitinib Products

WOWLY- Your AI Agent Apr 02, 2026 950 Views

Aarti Pharmalabs’ core business operations continue smoothly despite recent regulatory visits and legal challenges. The Delhi High Court has issued an order restraining the company from stockpiling, exporting, or selling pharmaceutical products containing Ruxolitinib and its phosphate API. Regulatory oversight includes ledger and stock register examinations, highlighting the company’s commitment to compliance amid these developments.

Aarti Pharmalabs recently underwent a regulatory visit by the local commissioner, who inspected the company’s offices and took copies of key documents such as ledgers and stock registers. This scrutiny forms part of routine regulatory oversight to ensure adherence to pharmaceutical laws and standards. Despite these checks, the company confirmed that its overall business operations have remained unaffected and continue without disruption.

Separately, the Delhi High Court has intervened with an order specifically targeting Aarti Pharmalabs’ pharmaceutical products containing the drug compound Ruxolitinib and/or Ruxolitinib Phosphate API. The court has restrained the company from stockpiling, exporting, or selling such drugs. This judicial intervention underscores ongoing legal and regulatory challenges surrounding certain pharmaceutical compounds, possibly linked to patent, safety, or regulatory compliance issues.

Key highlights:

Aarti Pharmalabs’ business operations remain unaffected despite regulatory scrutiny and court orders.
Local commissioner conducted an office visit, reviewing ledgers and stock registers for compliance.
Delhi High Court restrains the company from engaging in stockpiling, export, and sale of Ruxolitinib-based drugs.
Order pertains to pharmaceutical products containing Ruxolitinib and Ruxolitinib Phosphate API.
The company emphasizes adherence to legal and regulatory frameworks during investigations.
Legal restrictions could impact supply chain and international market activities related to these drugs.
Ongoing monitoring ensures pharmaceutical standards and intellectual property rights enforcement.
Aarti Pharmalabs remains committed to transparent operations amidst regulatory challenges.
The case highlights the sensitive nature of drug approvals and marketing in regulated markets.

The developments reflect heightened regulatory vigilance within the pharmaceutical sector and the company’s proactive stance to maintain operational continuity while complying with judicial mandates.

Sources: NSE India, Economic Times, Moneycontrol

Stay Ahead – Explore Now! India May Fuel Sales Drop 6.5% Y/Y to 19.93 Million Metric Tons